ALTERITY THERAPEUTICS-ADR (ATHE) Stock News

USA - NASDAQ:ATHE - US02155X2053 - ADR

4.48 USD

+0.1 (+2.28%)

Last: 9/19/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ATHE Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

7 days ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

14 days ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

14 days ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

20 days ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Present at the Biotech Showcase

20 days ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics to Present at the Biotech Showcase

2 months ago - By: ALTERITY THERAPEUTICS LIMITED

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

2 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

2 months ago - By: Benzinga - Mentions: PBM SCLX ABP CANF ...

12 Health Care Stocks Moving In Monday's Intraday Session

2 months ago - By: Benzinga - Mentions: CAMP ABP HCTI ADAP ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

2 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

2 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

2 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

2 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

3 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

3 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

4 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Prominently Featured at the International MSA Congress

4 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Prominently Featured at the International MSA Congress

5 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

5 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

5 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

5 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

5 months ago - By: ALTERITY THERAPEUTICS LIMITED

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

5 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

5 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

5 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

5 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

5 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

6 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

6 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

6 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

6 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

7 months ago - By: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Raises A$40.0 million in Placement

7 months ago - By: ALTERITY THERAPEUTICS LIMITED - Mentions: ASX -

Alterity Therapeutics Raises A$40.0 million in Placement